Hal joined GSK and was appointed to the Board on 1 January 2018. He was appointed as Chief Scientific Officer and President, R&D on 1 April 2018. He transitioned to the role of Non-Executive Director with additional responsibilities to support R&D on 1 August 2022.
Hal has had a distinguished career in biosciences, with a strong track record of research and development (R&D). In his former role at GSK as Chief Scientific Officer and President, R&D, where he brought a new approach to R&D, which focused on science related to the immune system, the use of human genetics and advanced technologies to help identify the next generation of transformational medicines. When he transitioned to a Non-Independent Non-Executive Director in August 2022, he assumed additional responsibilities to support R&D.
Before joining GSK, Hal was President, R&D at Calico LLC (California Life Company), an Alphabet-funded company that uses advanced technologies to increase understanding of lifespan biology. Hal was previously Executive Vice President, Head of Global Product Development, and Chief Medical Officer of Roche, responsible for all the products in the combined portfolio of Roche and Genentech. At Genentech, he was Senior Vice President of Development and Chief Medical Officer. Hal was a Non-Executive Director and Chair of the Science & Technology Committee at Juno Therapeutics, Inc until March 2018, when it was acquired by Celgene Corporation. He previously served as a Non-Executive Board Director of GRAIL, Inc and an Advisory Board Member of Verily Life Sciences LLC.
External appointments:
- CEO and Board Co-Chair, Altos Labs Inc
- Associate Adjunct Professor, Epidemiology & Biostatistics, University of California, San Francisco
